Asthma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others), By Mode of Administration (Inhalers, Nebulizers, Oral Medications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 28.92 Billion
CAGR (2026-2031)	4.62%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America
Market Size (2031)	USD 37.92 Billion

Market Overview

The Global Asthma Treatment Market will grow from USD 28.92 Billion in 2025 to USD 37.92 Billion by 2031 at a 4.62% CAGR. The global asthma treatment market comprises a diverse range of pharmacological interventions and delivery devices, including inhaled corticosteroids, bronchodilators, and biologic therapies, designed to manage chronic airway inflammation and alleviate acute constriction. The primary drivers supporting market expansion are the rising global prevalence of respiratory conditions attributed to rapid urbanization, deteriorating air quality, and increased exposure to environmental allergens. This escalating disease burden necessitates effective long-term management strategies, thereby fueling consistent demand for therapeutic products. According to the Global Initiative for Asthma, in 2024, the disease affected over 260 million individuals and caused approximately 450,000 deaths annually worldwide, highlighting the urgent and growing necessity for accessible medical interventions.

Despite these strong growth indicators, the market faces a significant impediment regarding the affordability and accessibility of advanced treatments. The high cost associated with biologic drugs and next-generation inhaler technologies restricts patient access, particularly in low-to-middle-income regions where healthcare reimbursement frameworks are limited. Furthermore, inconsistent patient adherence to prescribed medication regimens remains a substantial barrier, reducing treatment efficacy and limiting the potential revenue realization for pharmaceutical manufacturers. This challenge of economic and behavioral compliance continues to complicate the widespread expansion of the global asthma treatment sector.

Key Market Drivers

The escalating global prevalence of asthma and chronic respiratory disorders acts as the fundamental catalyst for market expansion, driven primarily by rapid urbanization and intensifying exposure to environmental pollutants. This surge in patient volume creates a sustained, necessity-based demand for effective maintenance therapies, as healthcare systems worldwide struggle to manage the growing burden of airway inflammation. The direct commercial impact of this rising disease incidence is evident in the performance of established maintenance treatments, which remain essential for controlling daily symptoms in the broader patient population. For instance, according to GSK, February 2025, sales of its respiratory maintenance therapy Trelegy increased by 27% in 2024, reflecting the critical need for consistent disease management strategies in response to deteriorating respiratory health metrics globally.

Simultaneously, the increasing adoption of targeted biologic therapeutics and monoclonal antibodies is reshaping the market's value trajectory by addressing the unmet needs of severe, uncontrolled asthma phenotypes. These precision medicines, which inhibit specific inflammatory pathways such as those driven by eosinophils or IgE, offer superior efficacy over conventional corticosteroids, thereby commanding premium pricing and driving substantial revenue growth. The rapid uptake of next-generation agents illustrates this trend; according to AstraZeneca, February 2025, combined sales of its novel biologic Tezspire reached $1.22 billion for the full year 2024, underscoring the shift toward personalized care. Furthermore, the immense scale of this advanced segment is highlighted by the sector's leading assets; according to Regeneron, February 2025, global net sales of the blockbuster biologic Dupixent rose by 22% to $14.15 billion in 2024, demonstrating the dominant financial contribution of precision therapeutics to the overall global asthma treatment market.

Download Free Sample Report

Key Market Challenges

The high cost of advanced pharmacological interventions and delivery devices presents a substantial barrier to the growth of the Global Asthma Treatment Market. Although the clinical demand for biologics and next-generation inhalers is rising, the elevated pricing of these premium therapies limits their adoption, particularly in regions with restricted healthcare reimbursement. When patients face significant out-of-pocket expenses, they are statistically more likely to ration doses or forgo treatment entirely. This economic friction directly hampers market expansion by reducing the volume of prescription refills and shrinking the practical addressable market for pharmaceutical manufacturers.

This financial strain effectively disconnects the high prevalence of the disease from realized revenue. According to the Asthma and Allergy Foundation of America, in 2025, the annual economic cost of asthma was estimated to be approximately $82 billion in the United States, creating a severe burden that complicates funding for consistent care. Consequently, payers often impose strict formulary controls to manage these expenditures, which further throttles patient access to effective treatments. As long as economic accessibility remains misaligned with the growing disease burden, the market will struggle to reach its full commercial potential.

Key Market Trends

The development of sustainable, low-global warming potential (GWP) inhalers is establishing a new competitive standard as manufacturers align respiratory product portfolios with rigorous environmental governance. This trend involves re-engineering pressurized metered-dose inhalers (pMDIs) to utilize next-generation propellants like HFA-152a, which significantly reduce the carbon footprint of daily disease management without compromising clinical efficacy. This industrial pivot is exemplified by substantial capital allocation toward green manufacturing capabilities and reformulation programs. According to Chiesi Farmaceutici, June 2025, in the '2024 Sustainability Report', the company backed its carbon-minimal inhaler program with a strategic investment of over €350 million to replace current propellants, aiming to reduce the product's carbon footprint by up to 90% and ensure long-term regulatory compliance.

Simultaneously, the market entry of cost-effective biosimilars and complex generics is reshaping the commercial landscape by challenging the exclusivity of established biologic therapies for severe asthma. As patent protection for blockbuster monoclonal antibodies expires, the approval of interchangeable biosimilars provides payers and healthcare systems with lower-cost alternatives, thereby expanding patient access to high-value treatments that were previously restricted by budget constraints. This shift toward more affordable precision medicine is gaining regulatory momentum. According to Celltrion, March 2025, in the press release 'FDA Approves Omlyclo as First Interchangeable Biosimilar to Xolair', the company secured U.S. regulatory clearance for its omalizumab biosimilar, a milestone that introduces price competition against the reference product and broadens the addressable market for biologic-grade asthma care.

Segmental Insights

The Online Pharmacies segment represents the fastest growing distribution channel in the Global Asthma Treatment Market, driven by the shift toward digital healthcare accessibility. Patients increasingly prioritize the convenience of doorstep delivery for maintenance medications, significantly reducing the need for physical pharmacy visits. This trend is supported by the widespread adoption of telemedicine services which integrate directly with digital prescription fulfillment platforms. Furthermore, clear guidelines from regulatory bodies regarding the sale of prescription drugs online have bolstered patient confidence, ensuring that these digital channels provide a safe and reliable source for essential respiratory therapies.

Regional Insights

North America maintains a dominant position in the global asthma treatment market, driven primarily by the rising prevalence of respiratory disorders and a well-established healthcare sector. This leadership is supported by extensive research activities and the presence of major pharmaceutical manufacturers within the region. Additionally, the U.S. Food and Drug Administration provides a structured regulatory environment that facilitates the timely introduction of new therapeutic options. Comprehensive reimbursement coverage further enhances patient access to necessary medication, ensuring steady market activity. Consequently, these combined factors secure North America’s status as the primary revenue generator in this sector.

Recent Developments

• In May 2024, GSK announced positive headline results from its Phase III SWIFT-1 and SWIFT-2 clinical trials evaluating the efficacy of depemokimab in patients with severe asthma. The data demonstrated that this investigational ultra-long-acting biologic met its primary endpoints by achieving a statistically significant reduction in the annualized rate of clinically significant asthma exacerbations over a 52-week period compared to placebo. Designed to target interleukin-5 with high affinity, the drug offers a prolonged half-life that supports a six-month dosing interval. The company noted that these results highlight the potential for a new treatment regimen that provides sustained disease control with less frequent administration.
• In April 2024, AstraZeneca received expanded approval from the US Food and Drug Administration for its biologic medication, Fasenra, to treat younger pediatric patients. The regulatory decision authorized the use of the drug as an add-on maintenance treatment for children aged 6 to 11 years with severe eosinophilic asthma. This approval was based on pharmacodynamic and pharmacokinetic data from the TATE trial, which confirmed that the safety profile and efficacy in this younger age group were consistent with results observed in adults and adolescents. The expansion allows a broader demographic of patients with uncontrolled severe asthma to access this targeted interleukin-5 receptor blocker.
• In February 2024, Sanofi and Regeneron presented late-breaking data at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology regarding their biologic therapy, Dupixent. The results from the Phase IV VESTIGE clinical trial utilized advanced functional respiratory imaging to show that the treatment significantly reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma. The study revealed that patients receiving the drug experienced numerically greater improvements in airway volume and flow compared to those on placebo. These findings reinforced the therapy's ability to address airway remodeling and improve lung function by inhibiting key drivers of type 2 inflammation.
• In January 2024, AstraZeneca announced the commercial availability of its first-in-class rescue inhaler, Airsupra, in the United States market. This product, which combines albuterol and budesonide, is the first Food and Drug Administration-approved medication to provide rapid symptom relief while simultaneously treating underlying airway inflammation. The launch was supported by results from the MANDALA and DENALI Phase III trials, which demonstrated that the combination therapy significantly reduced the risk of severe asthma exacerbations compared to albuterol alone. Company executives highlighted that this development addresses a critical gap in asthma care by mitigating inflammatory drivers during acute rescue use.

Key Market Players

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

By Drug Class	By Mode of Administration	By Distribution Channel	By Region
Short-Acting Beta-Agonists (SABA) Long-Acting Beta-Agonists (LABA) Inhaled Corticosteroids (ICS) Leukotriene Modifiers Immunomodulators Combination Drugs Others	Inhalers Nebulizers Oral Medications	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Asthma Treatment Market, By Drug Class:

• Short-Acting Beta-Agonists (SABA)
• Long-Acting Beta-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Leukotriene Modifiers
• Immunomodulators
• Combination Drugs
• Others

• Asthma Treatment Market, By Mode of Administration:

• Inhalers
• Nebulizers
• Oral Medications

• Asthma Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

• Asthma Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE